Weekly Administration of Irinotecan (CPT-11) plus Cisplatin for Non-small Cell Lung Cancer

Background: Weekly administration of irinotecan plus cisplatin was evaluated for untreated patients with non-small cell lung cancer (NSCLC). Patients and Methods: Sixty mg/m 2 of irinotecan plus 30 mg/m 2 of cisplatin were administered on days 1, 8 and 15 every 4 weeks. Patients with no evidence of...

Full description

Saved in:
Bibliographic Details
Published in:Anticancer research 2006-11, Vol.26 (6C), p.4697-4703
Main Authors: HINO, Mitsunori, KOBAYASHI, Kunihiko, YOSHIMURA, Akinobu, TAKEDA, Yuichiro, HISAKATSU, Shoji, YONEDA, Shuichi, GEMMA, Akihiko, MORIYA, Hiroshi, KUDOH, Shoji
Format: Article
Language:English
Subjects:
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols - administration & dosage
Antineoplastic Combined Chemotherapy Protocols - adverse effects
Biological and medical sciences
Camptothecin - administration & dosage
Camptothecin - adverse effects
Camptothecin - analogs & derivatives
Carcinoma, Non-Small-Cell Lung - drug therapy
Cisplatin - administration & dosage
Cisplatin - adverse effects
Drug Administration Schedule
Female
Humans
Lung Neoplasms - drug therapy
Male
Medical sciences
Middle Aged
Pneumology
Survival Rate
Tumors
Tumors of the respiratory system and mediastinum
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background: Weekly administration of irinotecan plus cisplatin was evaluated for untreated patients with non-small cell lung cancer (NSCLC). Patients and Methods: Sixty mg/m 2 of irinotecan plus 30 mg/m 2 of cisplatin were administered on days 1, 8 and 15 every 4 weeks. Patients with no evidence of disease progression were treated with at least two cycles (8 weeks). Of the 39 patients, 29 were provided an antidiarrheal program consisting of sodium bicarbonate and magnesium oxide. Results: There were 13 partial responses and an overall response rate of 33.3% [95% CI: 20%-50%]. The median time to progression and survival were 64 days and 12.8 months, respectively. Grade 4 neutropenia occurred in 15.4% of the patients, and Grade 3 and 4 diarrhea was observed in 12.8% and 2.6%, respectively. The incidence of leukopenia of grade 3-4 was significantly lower in patients provided with the antidiarrheal program due to lack of decrease in the lymphocyte count. Conclusion: This phase II study indicated that weekly irinotecan plus cisplatin administration was a promising treatment for untreated NSCLC.
ISSN:0250-7005
1791-7530